Resistance and virological response analyses in a three initial treatment strategy trial: A substudy of the INITIO trial

HIV Clinical Trials

Volumn 10, Issue 6, 2009, Pages 385-393

  Descamps, Diane ^a   Chazallon, Corine ^b   Loveday, Clive ^c   Bacheler, Lee ^d   Goodall, Ruth ^e   Yéni, Patrick ^a   Cooper, David A ^f   Babiker, Abdel ^e   Aboulker, Jean Pierre ^b   Brun Vézinet, Francoise ^a  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c Intl Clinical Virology Centre   (United Kingdom)

^d VircoLab Inc   (United States)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HIV 1; Mutations; Resistance; Virco TYPE

Indexed keywords

EFAVIRENZ; NELFINAVIR; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

BENZOXAZINES; DIDANOSINE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOME, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIROLOGY;

EID: 76749085768     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1006-385     Document Type: Article

References (15)

1. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563-608.
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
3. Yeni P, Cooper DA, Aboulker JP, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing nonnucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006;368(9532):287-298.
4. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14(3):125-130.
5. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr. 2005;38(5):545-552.
6. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192(6):958-966.
7. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331(7529):1368.
8. Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drugresistant HIV in Denmark during 1997-2004. Antivir Ther. 2006;11(5):591-600.
9. Dunn D, Geretti AM, Green H, et al. Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 2008;13(6):771-777.
10. de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviralexperienced HIV-infected patients. AIDS Res Hum Retroviruses. 2007;23(7):879-885.
11. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17(18):2635-2643.
12. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887-895.
13. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on firstline antiretroviral therapy effectiveness. Antivir Ther. 2005;10(2):247-254.
14. De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N. Viral load and CD4 cell response to protease inhibitorcontaining regimens in subtype B versus non-B treatmentnaive HIV-1 patients. AIDS. 2004;18(17):2330-2331.
15. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 2002;16(8): 1139-1146.